Paraoxonase, arylesterase and lactonase activities of paraoxonase-1 (PON1) in obese and severely obese women

References

• Mackness M, Mackness B. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567:12–21.
   PubMed Web of Science ®Google Scholar
• Rosenblat M, Gaidukov L, Khersonsky O, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem. 2006;281:7657–7665.
   PubMed Web of Science ®Google Scholar
• Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci. 2009;46:83–106.
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892–904.
   PubMed Web of Science ®Google Scholar
• Harel M, Aharoni A, Gaidukov L, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004;11:412–419.
   PubMed Web of Science ®Google Scholar
• Draganov DI, Teiber JF, Speelman A, et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46:1239–1247.
   PubMed Web of Science ®Google Scholar
• Tang WHW, Hartiala J, Fan Y, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012;32:2803–2812.
   PubMed Web of Science ®Google Scholar
• Tward A, Xia Y-R, Wang X-P, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106:484–490.
   PubMed Web of Science ®Google Scholar
• Cervellati C, Wood PL, Romani A, et al. Oxidative challenge in Alzheimer's disease: state of knowledge and future needs. J Investig Med. 2016;64:21–32.
   PubMed Web of Science ®Google Scholar
• Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693–2708.
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581–1590.
   PubMed Web of Science ®Google Scholar
• Chernyavskiy I, Veeranki S, Sen U, et al. Atherogenesis: hyperhomocysteinemia interactions with LDL, macrophage function, paraoxonase 1, and exercise. Ann NY Acad Sci. 2016;1363:138–154.
   PubMed Web of Science ®Google Scholar
• Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis. 2006;187:74–81.
   PubMed Web of Science ®Google Scholar
• Rozenberg O, Rosenblat M, Coleman R, et al. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med. 2003;34:774–784.
   PubMed Web of Science ®Google Scholar
• Castellazzi M, Trentini A, Romani A, et al. Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases. Int J Biochem Cell Biol. 2016;81:356–363.
   PubMed Web of Science ®Google Scholar
• Cervellati C, Trentini A, Romani A, et al. Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: a pilot study. J Neurochem. 2015;135:395–401.
   PubMed Web of Science ®Google Scholar
• Cervellati C, Romani A, Bergamini CM, et al. PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer's disease or vascular dementia. Clin Chem Lab Med. 2015;53:1049–1056.
   PubMed Web of Science ®Google Scholar
• Martinelli N, Girelli D, Olivieri O, et al. Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin Chem Lab Med. 2009;47:432–440.
   PubMed Web of Science ®Google Scholar
• Mastorikou M, Mackness B, Liu Y, et al. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med. 2008;25:1049–1055.
   PubMed Web of Science ®Google Scholar
• Ferretti G, Bacchetti T, Nègre-Salvayre A, et al. Structural modifications of HDL and functional consequences. Atherosclerosis. 2006;184:1–7.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest. 2013;123:3815–3828.
   PubMed Web of Science ®Google Scholar
• Mineo C, Shaul PW. PON-dering differences in HDL function in coronary artery disease. J Clin Invest. 2011;121:2545–2548.
   PubMed Web of Science ®Google Scholar
• Keaney JF, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham study. Arterioscler Thromb Vasc Biol. 2003;23:434–439.
   PubMed Web of Science ®Google Scholar
• Cremonini E, Bonaccorsi G, Bergamini CM, et al. Metabolic transitions at menopause: in post-menopausal women the increase in serum uric acid correlates with abdominal adiposity as assessed by DXA. Maturitas. 2013;75:62–66.
   PubMed Web of Science ®Google Scholar
• Cervellati C, Bonaccorsi G, Cremonini E, et al. Waist circumference and dual-energy X-ray absorptiometry measures of overall and central obesity are similarly associated with systemic oxidative stress in women. Scand J Clin Lab Investig. 2014;74:102–107.
   PubMed Web of Science ®Google Scholar
• Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol. 2013;4:71.
   PubMedGoogle Scholar
• Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, et al. Diagnosis and management of diabetes: synopsis of the 2016 American diabetes association standards of medical care in diabetes guideline development and evidence grading. Ann Intern Med. 2016;164:542–552.
   PubMed Web of Science ®Google Scholar
• Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American heart association, the American college of cardiology, and the centers for disease control and prevention. Hypertens (Dallas, TX 1979). 2014;63:878–885.
   PubMed Web of Science ®Google Scholar
• Barathi S, Angayarkanni N, Pasupathi A, et al. Homocysteinethiolactone and paraoxonase: novel markers of diabetic retinopathy. Diabetes Care. 2010;33:2031–2037.
   PubMed Web of Science ®Google Scholar
• DeLong JM, Prange RK, Hodges DM, et al. Using a modified ferrous oxidation-xylenol orange (FOX) assay for detection of lipid hydroperoxides in plant tissue. J Agric Food Chem. 2002;50:248–254.
   PubMed Web of Science ®Google Scholar
• Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32:2813–2820.
   PubMed Web of Science ®Google Scholar
• Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010;2010:802078.
   PubMed Web of Science ®Google Scholar
• Cervellati C, Bonaccorsi G, Bergamini CM, et al. Association between circulatory levels of adipokines and bone mineral density in postmenopausal women. Menopause. 2016;23:984–992.
   PubMed Web of Science ®Google Scholar
• Thomàs-Moyà E, Gómez-Pérez Y, Fiol M, et al. Gender related differences in paraoxonase 1 response to high-fat diet-induced oxidative stress. Obesity (Silver Spring). 2008;16:2232–2238.
   PubMed Web of Science ®Google Scholar
• Ferretti G, Bacchetti T, Moroni C, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2005;90:1728–1733.
   PubMed Web of Science ®Google Scholar
• Ferretti G, Bacchetti T, Masciangelo S, et al. HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity (Silver Spring). 2010;18:1079–1084.
   PubMed Web of Science ®Google Scholar
• Ferré N, Feliu A, García-Heredia A, et al. Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. Clin Biochem. 2013;46:1830–1836.
   PubMed Web of Science ®Google Scholar
• Tabur S, Torun AN, Sabuncu T, et al. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol. 2010;162:535–541.
   PubMed Web of Science ®Google Scholar
• Gonzalez V, Huen K, Venkat S, et al. Cholinesterase and paraoxonase (PON1) enzyme activities in Mexican-American mothers and children from an agricultural community. J Expos Sci Environ Epidemiol. 2012;22:641–648.
   PubMed Web of Science ®Google Scholar
• Ferre N. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem. 2003;49:1491–1497.
   PubMed Web of Science ®Google Scholar
• bin Ali A, Zhang Q, Lim YK, et al. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic Biol Med. 2003;34:824–829.
   PubMed Web of Science ®Google Scholar
• James RW, Brulhart-Meynet MC, Singh AK, et al. The scavenger receptor class B, type i is a primary determinant of paraoxonase-1 association with high-density lipoproteins. Arterioscler Thromb Vasc Biol. 2010;30:2121–2127.
   PubMed Web of Science ®Google Scholar
• Costa LG, Vitalone A, Cole TB, et al. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005;69:541–550.
   PubMed Web of Science ®Google Scholar
• Kunutsor SK, Bakker SJL, James RW, et al. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: the PREVEND study and meta-analysis of prospective population studies. Atherosclerosis. 2016;245:143–154.
   PubMed Web of Science ®Google Scholar
• Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation. 2003;107:2775–2779.
   PubMed Web of Science ®Google Scholar
• Huen K, Richter R, Furlong C, et al. Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta. 2009;402:67–74.
   PubMed Web of Science ®Google Scholar
• Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol. 2001;21:1451–1457.
   PubMed Web of Science ®Google Scholar
• Marsillach J, Aragonès G, Beltrán R, et al. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem. 2009;42:91–98.
   PubMed Web of Science ®Google Scholar
• Billecke S, Draganov D, Counsell R, et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000;28:1335–1342.
   PubMed Web of Science ®Google Scholar
• Ceron JJ, Tecles F, Tvarijonaviciute A. Serum paraoxonase 1 (PON1) measurement: an update. BMC Vet Res. 2014;10:74.
   PubMed Web of Science ®Google Scholar
• Teiber JF, Draganov DI, La Du BN. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol. 2003;66:887–896.
   PubMed Web of Science ®Google Scholar